Listing 7.02 Chronic Anemia in 2026: Why the Old Hematocrit 30 Percent Rule No Longer Exists, How SSA Now Evaluates Chronic Anemia Through 7.05 Hemolytic Anemias and 7.10 Bone Marrow Failure, and the Three Numbers You Actually Need to Meet a Step 3 Listing

By Anthony Albert, Benefits Research Director. Published July 22, 2026.

If you searched "SSDI Listing 7.02" or "chronic anemia disability" and landed on an article telling you that a hematocrit of 30 percent or less qualifies you, that article is out of date. The rule you are reading about was pulled out of the Blue Book on May 18, 2015 when SSA rewrote all of Section 7.00 Hematological Disorders. Old law-firm pages, old Q and A forums, and even a few state disability determination handouts still quote the 30 percent number. It does not exist as a Step 3 rule anymore.

Chronic anemia claims still get approved every day in 2026. They just get approved through different math. This article walks through the current SSA rules, gives you the three specific numbers that meet Step 3, and shows how a claim that would have qualified under the old 7.02 language usually still qualifies under 7.05 for hemolytic causes or 7.10 for bone marrow failure causes. Real cases at the end.

What Listing 7.02 Used to Say and Why It Was Deleted

Before May 2015, SSA had a standalone listing called 7.02 Chronic Anemia. The rule was short. You met it with a hematocrit persisting at 30 percent or less due to any cause, plus one of two paragraphs:

• Paragraph A: a required blood transfusion an average of at least once every 2 months, or
• Paragraph B: evaluation of the resulting impairment under criteria for the affected body system.

Paragraph B was a pointer, not a rule. Paragraph A was the real listing test. SSA repealed the 7.02 language when it rewrote Section 7.00 for two reasons that the Federal Register notice spelled out. First, hematocrit alone does not predict function. A person with sickle cell hemoglobin at hematocrit 22 percent can be walking and working while a person with acute post-hemorrhage hematocrit 28 percent can be bedbound. Second, the transfusion-once-every-2-months rule was rarely met in 2015 because chronic transfusion protocols had shifted to every 3 or 4 weeks for most transfusion-dependent conditions.

SSA replaced the general chronic anemia rule with cause-specific listings. Anemia from a hemolytic cause goes under 7.05. Anemia from bone marrow failure goes under 7.10. Anemia from repeated complications of any hematological disorder goes under 7.18. Anemia from a body system disease like chronic kidney disease anemia or chronic heart failure anemia gets evaluated under that body system, not under 7.00 at all.

The three numbers that replaced the old 30 percent rule

If you take nothing else from this article, take these three numbers. They are the ones that get chronic anemia claims approved at Step 3 in 2026:

1. Hemoglobin 7.0 g/dL or less, three times in a 12 month period, at least 30 days apart. This is Listing 7.05C for hemolytic anemias.
2. Transfusion at least once every 6 weeks. This is Listing 7.05D for beta thalassemia major and Listing 7.10B for MDS and aplastic anemia.
3. Three hospitalizations of 48 hours or more in 12 months, at least 30 days apart. This is Listing 7.05B (hemolytic anemia complications) and Listing 7.10A (bone marrow failure complications).

Every current chronic anemia Step 3 approval funnels through one of those three numbers, plus 6 vaso-occlusive crises requiring parenteral narcotics for sickle cell under 7.05A. That is the whole Section 7 chronic anemia menu now.

Route 1: Hemolytic Anemias Under Listing 7.05

Hemolytic anemia is any condition where red blood cells are being destroyed faster than the bone marrow can replace them. The cause can be inherited or acquired. Under the current 7.05, you have four ways to meet the listing.

7.05A: Painful vaso-occlusive crises

You meet 7.05A with at least 6 documented painful crises requiring parenteral (intravenous or intramuscular) narcotic medication within a 12 month period, with at least 30 days between crises. This is really a sickle cell rule. Hereditary spherocytosis does not usually cause vaso-occlusive crises. Sickle cell HbSS, HbSC, and sickle beta thalassemia can. The crisis has to be documented, not just reported. That means an ED note, an infusion clinic note, or an inpatient note that shows the parenteral narcotic dose. Oral morphine equivalents do not count.

7.05B: Three hospitalizations for complications

You meet 7.05B with at least 3 hospitalizations within a 12 month period, at least 30 days apart, each lasting at least 48 hours. The 48 hours can include time in the ED or a federally designated sickle cell center immediately before admission. The complications do not have to be the same across all three. Osteomyelitis, acute chest syndrome, splenic sequestration, gallbladder disease, stroke, hepatic failure, renal failure, aplastic crisis, and severe pain crisis all count.

7.05C: Hemoglobin 7.0 g/dL or less

This is the closest current analog to the old 7.02 hematocrit rule. You meet 7.05C with hemoglobin measurements of 7.0 g/dL or less, at least 3 times within a 12 month period, with at least 30 days between measurements. Notice the switch from hematocrit to hemoglobin. Hematocrit fluctuates with hydration and lab technique. Hemoglobin is a direct measurement. If you convert the old 30 percent hematocrit to hemoglobin, you get roughly 10 g/dL. The new 7.05C threshold at 7.0 g/dL is much more severe. Under the old 7.02, a moderate anemia met the listing. Under 7.05C, only severe anemia meets it.

7.05D: Beta thalassemia major on transfusion

You meet 7.05D with beta thalassemia major requiring lifelong red blood cell transfusions at least once every 6 weeks to maintain life. This is the direct replacement for the old 7.02A transfusion rule. The frequency loosened from every 2 months to every 6 weeks, which reflects real transfusion protocols. Most transfusion-dependent thalassemia patients get transfused every 3 to 4 weeks, so this criterion is often clearly met.

Route 2: Bone Marrow Failure Under Listing 7.10

Bone marrow failure means the marrow cannot make enough red cells, white cells, and platelets. Aplastic anemia is the classic example. Myelodysplastic syndromes (MDS), granulocytopenia, and myelofibrosis also fall here. Listing 7.10 has two paragraphs.

7.10A: Three hospitalizations for complications

Same structure as 7.05B. Three hospitalizations in 12 months, at least 30 days apart, each 48 hours or longer, ED time counts. Complications can include severe infection due to neutropenia, bleeding due to thrombocytopenia, cardiac complications from severe anemia, or transfusion reactions.

7.10B: Lifelong RBC transfusions every 6 weeks

Same 6 week transfusion threshold as 7.05D but applied to MDS or aplastic anemia requiring lifelong red blood cell transfusions at least once every 6 weeks to maintain life. Many MDS patients who become transfusion dependent hit this criterion within a year of diagnosis. Aplastic anemia patients who fail immunosuppression or are not candidates for stem cell transplant also hit it.

7.17: Post-transplant automatic 12 months

If you get a bone marrow or stem cell transplant for any of these conditions, Listing 7.17 grants you disability for at least 12 consecutive months from the date of transplantation. After 12 months, SSA evaluates any residual impairment under the appropriate body system. This is not a chronic anemia route, but it is often relevant for the same underlying diagnosis.

Route 3: Repeated Complications Under Listing 7.18

Listing 7.18 is the functional escape valve when your anemia does not quite hit the numeric thresholds in 7.05 or 7.10. You meet 7.18 with repeated complications of a hematological disorder plus marked limitation in one of three functional areas: activities of daily living, social functioning, or completing tasks due to deficiencies in concentration, persistence, or pace.

Repeated complications means three complications within 12 months lasting at least 2 weeks each, or shorter complications occurring more frequently than 3 per year, or less frequent but longer complications averaging to the same total impact. This is a three-way frequency and duration test. The complications and the marked limitation both have to be documented.

7.18 is where a chronic anemia claim goes when hemoglobin runs 8 to 9 g/dL rather than 7.0 or less, when transfusions run every 8 to 12 weeks rather than every 6, or when the picture is dominated by fatigue, dyspnea, and cognitive slowing rather than by discrete hospitalizations. If your fatigue and cognitive impact are documented in ADL forms, third-party statements, and treating physician RFC assessments, 7.18 can still get you to a Step 3 approval.

Route 4: Body System Referral

Section 7.00 explicitly says that anemia from a body system disease gets evaluated under that body system. This is where the old 7.02 Paragraph B pointer still lives, just implicitly.

• Anemia of chronic kidney disease: evaluate under Listing 6.03 chronic kidney disease with dialysis, 6.04 chronic kidney disease with kidney transplant, or 6.05 chronic kidney disease with complications.
• Anemia of chronic heart failure: evaluate under Listing 4.02 chronic heart failure.
• Anemia from chronic inflammatory disease: evaluate under Listing 14.05 undifferentiated CTD, 14.06 mixed CTD, 14.07 inflammatory arthritis, or the specific inflammatory listing that fits.
• Anemia from chronic liver disease: evaluate under 5.05 chronic liver disease.
• Anemia from chemotherapy for a cancer: evaluate under the specific 13.00 malignant listing.

The referral rule matters because a chronic anemia claim that looks weak under 7.00 may be strong when refiled under the underlying body system. Kidney anemia at hemoglobin 9.5 g/dL will not meet 7.05C, but the underlying kidney disease at eGFR under 15 with dialysis or with 6.05 complications may meet the kidney listing on its own.

Documentation Checklist

Whether the claim runs through 7.05, 7.10, 7.17, 7.18, or a body system, the file has to build the right record.

1. Complete blood count records showing hemoglobin, hematocrit, MCV, RDW, reticulocyte count, and peripheral smear findings, with dates, at least three separate measurements 30 days apart for 7.05C.
2. Diagnosis-confirming lab work. For hemolytic anemia this is hemoglobin electrophoresis, membrane defect testing, enzyme testing, or DAT (Coombs) for autoimmune hemolytic anemia. For bone marrow failure this is a bone marrow biopsy report with cellularity percentage, morphology, and cytogenetics.
3. Transfusion records with dates, unit counts, and hemoglobin pre- and post-transfusion. Blood bank transaction logs are the strongest evidence.
4. Hospitalization records with admission notes, discharge summaries, and length of stay documentation. ED notes prior to admission count toward the 48 hour threshold.
5. Vaso-occlusive crisis documentation for sickle cell claims, including parenteral narcotic administration records.
6. Body system consultative work if referral applies. Nephrology notes for CKD anemia, cardiology notes for CHF anemia, rheumatology notes for inflammatory anemia.
7. Functional evidence including ADL forms, third-party function reports, and treating physician RFC assessments if 7.18 is in play.

Four Worked Cases

Case One, Marcus, 34, Georgia

Marcus has sickle cell HbSS with a history of 4 painful crises requiring IV morphine in the past 12 months and 2 hospitalizations for acute chest syndrome lasting 5 and 7 days. He also has hemoglobin values of 6.8, 7.1, and 6.5 g/dL over 4 separate CBCs in a 10 month window. He does not meet 7.05A because he only has 4 crises, not 6. He does not meet 7.05B because he only has 2 hospitalizations, not 3. But he does meet 7.05C because he has 3 hemoglobin measurements at 7.0 g/dL or less within 12 months at more than 30 days apart. SSDI approved at Step 3.

Case Two, Renee, 52, Ohio

Renee has MDS with refractory anemia and ring sideroblasts (RARS subtype). Bone marrow biopsy confirms diagnosis with 8 percent blasts and 15 percent ring sideroblasts. She has required transfusion every 3 to 4 weeks for the past 14 months, verified by blood bank records. She meets 7.10B because she has documented lifelong RBC transfusions at least once every 6 weeks to maintain life. SSDI approved.

Case Three, Priya, 41, Texas

Priya has aplastic anemia diagnosed after failed immunosuppression with ATG and cyclosporine. She is on the transplant list. In the past 12 months she has been hospitalized 3 times: once for neutropenic fever lasting 6 days, once for platelet count 4,000 with epistaxis and mucosal bleeding lasting 3 days, and once for a transfusion reaction with respiratory compromise lasting 2 days. All three hospitalizations were more than 30 days apart, all lasted at least 48 hours. She meets 7.10A. SSDI approved. If she gets the stem cell transplant during her disability period, 7.17 automatically extends her disability for 12 months post-transplant.

Case Four, Thomas, 58, Michigan

Thomas has anemia of chronic kidney disease at eGFR 22, hemoglobin running 8.5 to 9.5 g/dL despite erythropoietin and iron therapy. He does not meet 7.05C because his hemoglobin never falls to 7.0 or less. He does not meet any 7.10 criterion because his marrow is not failing. But his underlying CKD at eGFR 22 with the anemia, dyspnea on exertion, and secondary hyperparathyroidism gets evaluated under 6.05 CKD with complications. He does not meet 6.03 because he is not on dialysis. He does meet 6.05 because his renal disease with anemia at hemoglobin under 10.0 g/dL, plus his fluid overload, plus his fatigue are all documented. SSDI approved under 6.05, not 7.00.

Denial Counters

Denial reason: only 2 hemoglobin measurements at 7.0 or less

7.05C requires three measurements. Get a third CBC before appealing, if your treating hematologist is willing to check within the 12 month window. If the timeline has slipped, refile at reconsideration when a new low measurement is on record. Alternatively, argue equivalence to 7.05C with two very low measurements plus documented severe symptoms, or move to 7.18 with functional criteria.

Denial reason: transfusions every 8 weeks, not 6

7.05D and 7.10B require every 6 weeks. If your interval is 7 or 8 weeks, ask your hematologist whether the interval reflects medical stability or bank supply limitations. Some MDS patients get stretched to 8 weeks to conserve blood but would clinically require transfusion at 4 weeks. A physician statement documenting this can support argument for equivalence. 7.18 is also available if fatigue and functional impact are documented.

Denial reason: hospitalizations were only 24 to 36 hours

Check the ED clock. Section 7.00 allows ED time immediately before admission to count toward the 48 hour threshold. A 12 hour ED stay before an 40 hour inpatient stay hits 52 hours total. Ask the hospital for the full ED-to-discharge timeline, not just the inpatient admission time.

Denial reason: crisis pain was not documented as requiring IV narcotics

7.05A specifically requires parenteral narcotic medication. Oral hydromorphone or oral oxycodone does not count. Review your medication administration records (MARs). If IV morphine, IV hydromorphone, IV fentanyl, or IM meperidine was given, it should be on the MAR. If it was given but not clearly documented, ask the hospital for the pharmacy dispensing record.

State Considerations

Chronic anemia claims move through the same federal disability determination process in every state, but state DDS turnaround times and consultative exam quality vary. Higher-quality DDS states for hematology claims include Pennsylvania, Ohio, and Michigan. Long-turnaround states include Florida, Texas, and Georgia.

If you live in a federally designated Sickle Cell Center (CSCC) service area (10 nationwide), your file will typically move faster because DDS accepts CSCC records as authoritative documentation of crises and complications. If you are outside a CSCC area, your treating hematologist's notes carry the same weight but often require follow-up requests from DDS.

Related Blue Book Reading on This Site

• Listing 7.05 Hemolytic Anemias Including Sickle Cell Disease
• Listing 7.08 Disorders of Thrombosis and Hemostasis
• Listing 7.10 Bone Marrow Failure Disorders
• Listing 7.18 Repeated Complications of Hematological Disorders
• Listing 6.03 Chronic Kidney Disease Dialysis

Frequently Asked Questions